---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-011829"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2023-09-14T23:59:59+00:00"
generated_at: "2026-06-10T17:41:23.885713+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zomedica gets NYSE American deficiency notice for low share price (<$0.20 avg)

## Summary
- 30-trading day average share price fell below $0.20, triggering Section 1003(f)(v) non-compliance.
- Cure deadline is March 12, 2024; Company may effect a reverse stock split.
- No immediate delisting; shares continue trading on NYSE American during cure period.
- Management remains well-capitalized; business operations and SEC reporting unaffected.

## SEC filing metadata
- accession: 0001654954-23-011829
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2023-09-14T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495423011829/0001654954-23-011829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495423011829/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-011829
- JSON: https://secwatch.observer/filing/0001654954-23-011829.json
- Plain text: https://secwatch.observer/filing/0001654954-23-011829.txt

## Key facts
- Listing & Compliance Notices
  Zomedica Corp. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v), 1009).
  - Exchange: nyse american
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 1003(f)(v), 1009
  source text: September 12, 2023, Zomedica Corp. (the “Company”) received a deficiency letter (the “Letter”) from the NYSE American LLC (the “NYSE American”) indicating that the Company was not in compliance with the NYSE American continued listing standards set forth in Section 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”) because the Company’s common shares were selling for a substantial period of time at a low price per share, which the NYSE American determined to be a 30-trading day average of less than $0.20 per share. The Letter does not result in the immediate delisting of the C
  evidence_url: https://www.sec.gov/Archives/edgar/data/1684144/000165495423011829/0001654954-23-011829-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.